BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duvoux C, Toso C. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation? Transplant Rev (Orlando). 2015;29:168-174. [PMID: 26071984 DOI: 10.1016/j.trre.2015.02.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Guerrini GP, Esposito G, Olivieri T, Magistri P, Ballarin R, Di Sandro S, Di Benedetto F. Salvage versus Primary Liver Transplantation for Hepatocellular Carcinoma: A Twenty-Year Experience Meta-Analysis. Cancers (Basel) 2022;14:3465. [PMID: 35884526 DOI: 10.3390/cancers14143465] [Reference Citation Analysis]
2 Minjares RO, Martin P, Carrion AF. Chronic Kidney Disease After Liver Transplantation. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.006] [Reference Citation Analysis]
3 Chen Q, Lu X, Xie J, Ma N, Xu W, Zhang Z, Huang X, Liu H, Hou J, Zhang X, Zhu W. Analysis of L Antigen Family Member 3 as a Potential Biomarker and Therapeutic Target Associated With the Progression of Hepatocellular Carcinoma. Front Oncol 2022;12:813275. [DOI: 10.3389/fonc.2022.813275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shen B, Cen Z, Tan M, Song C, Wu X, Wang J, Huang M, Shen Y. Current Status of Malignant Tumors after Organ Transplantation. BioMed Research International 2022;2022:1-12. [DOI: 10.1155/2022/5852451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
6 Peruhova M, Peshevska-sekulovska M, Panayotova G, Velikova T. Foremost Concepts in Mechanisms of De Novo Post-Liver Transplantation Malignancy. Gastroenterology Insights 2021;12:283-92. [DOI: 10.3390/gastroent12030025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wei J, Ye L, Song L, Tang H, Zhang T, Fu B, Zhang Y, Yang Q, Yang Y, Yi S. TSC1/2 mutations-a unique type of mutation suitable for liver transplantation of Hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1074-85. [PMID: 34295558 DOI: 10.21037/jgo-20-378] [Reference Citation Analysis]
8 Sarici B, Isik B, Yilmaz S. Management of Recurrent HCC After Liver Transplantation. J Gastrointest Cancer 2020;51:1197-9. [PMID: 32839944 DOI: 10.1007/s12029-020-00498-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zhang Y, Solinas A, Cairo S, Evert M, Chen X, Calvisi DF. Molecular Mechanisms of Hepatoblastoma. Semin Liver Dis 2021;41:28-41. [PMID: 33764483 DOI: 10.1055/s-0040-1722645] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tan DJH, Wong C, Ng CH, Poh CW, Jain SR, Huang DQ, Muthiah MD. A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity. J Clin Med 2021;10:E238. [PMID: 33440759 DOI: 10.3390/jcm10020238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Lee KW, Kim SH, Yoon KC, Lee JM, Cho JH, Hong SK, Yi NJ, Han SS, Park SJ, Suh KS. Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial. J Clin Med 2020;9:E3264. [PMID: 33053849 DOI: 10.3390/jcm9103264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Deng LJ, Lei YH, Quan JY, Li BJ, Zhang DM, Tian HY, Chen Y, Zhang EX, Chen L, Ye WC, Ning WM, Yu LZ, Liu JS. 1β-OH-arenobufagin induces mitochondrial apoptosis in hepatocellular carcinoma through the suppression of mTOR signaling pathway. J Ethnopharmacol 2021;266:113443. [PMID: 33022344 DOI: 10.1016/j.jep.2020.113443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Saliba F, Duvoux C, Dharancy S, Dumortier J, Calmus Y, Gugenheim J, Kamar N, Salamé E, Neau-Cransac M, Vanlemmens C, Durand F, Pageaux G, Leroy V, Hardwigsen J, Gharbi H, Masson C, Tindel M, Conti F. Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years. Liver Transpl 2019;25:1822-32. [PMID: 31631501 DOI: 10.1002/lt.25664] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
14 Tejedor-Tejada J, Alonso-Martín C, Almohalla-Álvarez C, Valenzuela EF, Muñoz RN, Delgado LS, Martín CM, Sánchez-Martín F, García-Pajares F, Sánchez-Antolín G. Immunosuppressive Treatment With mTOR Inhibitors for Malignancies After Liver Transplantation: Long-Term Survival Retrospective Analysis. Transplant Proc 2020;52:1507-10. [PMID: 32213292 DOI: 10.1016/j.transproceed.2020.02.058] [Reference Citation Analysis]
15 Al-Ameri AAM, Wei X, Lin L, Shao Z, Guo H, Xie H, Zhou L, Zheng S, Xu X. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation. BMC Cancer. 2019;19:1136. [PMID: 31752756 DOI: 10.1186/s12885-019-6343-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Bedreli S, Straub K, Achterfeld A, Willuweit K, Katsounas A, Saner F, Wedemeyer H, Herzer K. The Effect of Immunosuppression on Coagulation After Liver Transplantation. Liver Transpl 2019;25:1054-65. [PMID: 31021493 DOI: 10.1002/lt.25476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Grigg SE, Sarri GL, Gow PJ, Yeomans ND. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2019;49:1260-1273. [PMID: 30989721 DOI: 10.1111/apt.15253] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
18 Tan PS, Muthiah MD, Koh T, Teoh YL, Chan A, Kow A, Zheng Q, Kwon CHD, Lee GH, Lesmana CRA, de Villa V, Fung J, Lim K. Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation. Transplantation 2019;103:470-80. [DOI: 10.1097/tp.0000000000002532] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
19 Guerrero M, Ferrín G, Rodríguez-Perálvarez M, González-Rubio S, Sánchez-Frías M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllón MD, Barrera P, Montero JL, de la Mata M. mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence.Int J Mol Sci. 2019;20. [PMID: 30650598 DOI: 10.3390/ijms20020336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
20 Dumortier J, Couchonnal E, Lacaille F, Rivet C, Debray D, Boillot O, Lachaux A, Ackermann O, Gonzales E, Wildhaber BE, Jacquemin E, McLin V. mTOR inhibitors in pediatric liver transplant recipients. Clin Res Hepatol Gastroenterol 2019;43:403-9. [PMID: 30528864 DOI: 10.1016/j.clinre.2018.11.010] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 Rodríguez-perálvarez M, Guerrero M, Barrera L, Ferrín G, Álamo JM, Ayllón MD, Artacho GS, Montero JL, Briceño J, Bernal C, Padillo J, Marín-gómez LM, Pascasio JM, Poyato A, Gómez-bravo MA, De la Mata M. Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. Transplantation 2018;102:2056-64. [DOI: 10.1097/tp.0000000000002270] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
22 Nashan B. mTOR Inhibition and Clinical Transplantation: Liver. Transplantation 2018;102:S19-26. [PMID: 28230639 DOI: 10.1097/TP.0000000000001690] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
23 Wang S, Zhu M, Wang Q, Hou Y, Li L, Weng H, Zhao Y, Chen D, Ding H, Guo J, Li M. Alpha-fetoprotein inhibits autophagy to promote malignant behaviour in hepatocellular carcinoma cells by activating PI3K/AKT/mTOR signalling. Cell Death Dis 2018;9:1027. [PMID: 30301886 DOI: 10.1038/s41419-018-1036-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
24 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019;1440:23-35. [PMID: 30221358 DOI: 10.1111/nyas.13971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
25 Allaire M, Bazille C, Selves J, Salamé E, Altieri M. Hepatitis E virus infection mimicking acute graft rejection in a liver transplant recipient. Clinics and Research in Hepatology and Gastroenterology 2018;42:e68-71. [DOI: 10.1016/j.clinre.2017.12.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
26 Satapathy SK, Das K, Kocak M, Helmick RA, Eason JD, Nair SP, Vanatta JM. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant. Clin Transplant. 2018;32:e13246. [PMID: 29577449 DOI: 10.1111/ctr.13246] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
27 Jeng LB, Lee SG, Soin AS, Lee WC, Suh KS, Joo DJ, Uemoto S, Joh J, Yoshizumi T, Yang HR. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant. 2018;18:1435-1446. [PMID: 29237235 DOI: 10.1111/ajt.14623] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
28 Guerrini GP, Pinelli D, Marini E, Corno V, Guizzetti M, Zambelli M, Aluffi A, Lincini L, Fagiuoli S, Lucianetti A, Colledan M. Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation. Prog Transplant 2018;28:63-9. [PMID: 29251164 DOI: 10.1177/1526924817746686] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 196] [Article Influence: 39.6] [Reference Citation Analysis]
30 Rubín Suárez A, Bilbao Aguirre I, Fernández-Castroagudin J, Pons Miñano JA, Salcedo Plaza M, Varo Pérez E, Prieto Castillo M. Recommendations of everolimus use in liver transplant. Gastroenterol Hepatol 2017;40:629-40. [PMID: 28743539 DOI: 10.1016/j.gastrohep.2017.05.008] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
31 Wong TC, Lo CM, Fung JY. Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation. Expert Opin Emerg Drugs 2017;22:123-36. [PMID: 28503959 DOI: 10.1080/14728214.2017.1330884] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
32 Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017;3:493-500. [PMID: 27838698 DOI: 10.1001/jamaoncol.2016.5116] [Cited by in Crossref: 111] [Cited by in F6Publishing: 104] [Article Influence: 22.2] [Reference Citation Analysis]
33 Weiler N, Bilge N, Troetschler S, Vermehren J, Schnitzbauer AA, Herrmann E, Sarrazin C, Zeuzem S, Welker MW. Conversion From Sirolimus to Everolimus in Long-Term Liver Graft Recipients. J Clin Pharmacol 2017;57:837-45. [PMID: 28134984 DOI: 10.1002/jcph.871] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
34 Burra P, Belli LS, Ginanni Corradini S, Volpes R, Marzioni M, Giannini E, Toniutto P. Common issues in the management of patients in the waiting list and after liver transplantation. Dig Liver Dis 2017;49:241-53. [PMID: 28096056 DOI: 10.1016/j.dld.2016.12.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
35 Xu S, Zhang Y, Wang G, Yang Q, Liu B, Zhang J, Li H, Wang G, Yang Y, Chen G. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2016;40:674-81. [DOI: 10.1016/j.clinre.2016.03.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
36 Tao J, Xu E, Zhao Y, Singh S, Li X, Couchy G, Chen X, Zucman-Rossi J, Chikina M, Monga SP. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin. Hepatology 2016;64:1587-605. [PMID: 27097116 DOI: 10.1002/hep.28601] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 11.3] [Reference Citation Analysis]
37 Tarantino G, Magistri P, Ballarin R, Di Francia R, Berretta M, Di Benedetto F. Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature. Front Pharmacol 2016;7:387. [PMID: 27818634 DOI: 10.3389/fphar.2016.00387] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
38 Holdaas H, De Simone P, Zuckermann A. Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. J Transplant 2016;2016:4369574. [PMID: 27807479 DOI: 10.1155/2016/4369574] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
39 Kim SS, Kang TW, Song KD, Cho SK, Lee MW, Rhim H, Sinn DH, Jung SH. Radiofrequency ablation and transarterial chemoembolisation as first-line treatment for recurrent hepatocellular carcinoma or isolated intrahepatic recurrent hepatocellular carcinoma in transplanted livers. Clin Radiol 2017;72:141-9. [PMID: 27742104 DOI: 10.1016/j.crad.2016.09.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
40 Dumortier J, Dharancy S, Calmus Y, Duvoux C, Durand F, Salamé E, Saliba F. Use of everolimus in liver transplantation: The French experience. Transplantation Reviews 2016;30:161-70. [DOI: 10.1016/j.trre.2015.12.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
41 Aerts M, Benteyn D, Van Vlierberghe H, Thielemans K, Reynaert H. Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 253-261 [PMID: 26755874 DOI: 10.3748/wjg.v22.i1.253] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
42 Bhat M, Watt KD. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk? Clin Transplant 2015;29:654-63. [DOI: 10.1111/ctr.12559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]